ResMed Inc.'s Sleep Apnea Leadership Faces Growing Competition
· dev
Sleep Apnea’s Growth Engine Hits a Snag
ResMed Inc.’s recent financials paint a rosy picture, with revenue growth driven by its robust product portfolio, led by the AirSense platform. However, beneath this facade lies a more complex reality: the return of Philips Respironics to the US market looms large as a potential game-changer.
The global obstructive sleep apnea (OSA) treatment market is experiencing unprecedented growth, fueled in part by increased awareness and penetration. ResMed’s diverse product offerings – from CPAP machines to masks and accessories – have enabled it to capture recurring revenue streams beyond initial device sales. This business model has proven resilient in the face of growing competition, as evidenced by the company’s 9% year-over-year revenue increase in the fourth quarter of fiscal 2026.
ResMed’s strong presence in the Americas market is a key driver behind its success. The region accounts for a significant portion of the company’s revenue, and recent growth has been particularly impressive, with Americas device revenue increasing by 6% and total Americas Sleep and Breathing Health revenue rising by 8%. This performance underscores ResMed’s ability to monetize its installed patient base beyond the initial device purchase.
Analysts at RBC Capital are bullish on ResMed’s prospects, predicting high single-digit earnings per share growth over the next three years. However, their optimism is tempered by concerns surrounding Philips Respironics’ potential return to the US market. There is currently no concrete timeline for this eventuality, but its impact could be substantial if it disrupts ResMed’s dominance.
Recent upgrades from research firms have further boosted investor confidence in ResMed. On September 15, RBC Capital upgraded the company’s stock to Outperform and raised its price target to $262 from $244. While this positive sentiment is well-deserved, given ResMed’s leadership position in OSA devices, it also underscores the risks associated with a competitive market.
ResMed is not immune to threats in the sleep apnea treatment space. The absence of Philips Respironics has created a temporary advantage for the company, but its return would undoubtedly pile pressure on sales. Furthermore, the firm’s recent guidance fell short of Wall Street expectations, casting a shadow over its growth prospects.
The convergence of these factors raises questions about ResMed’s ability to maintain its market leadership in the face of escalating competition. While the company’s robust product portfolio and diverse revenue streams provide a solid foundation for future success, the return of Philips Respironics would undoubtedly test ResMed’s mettle.
As investors weigh their options, they must consider the broader implications of this story. The answer lies not only in ResMed’s financials but also in its ability to innovate and adapt to changing market conditions. Will ResMed be able to maintain its dominance in the OSA treatment market, or will Philips Respironics’ return disrupt the status quo? Ultimately, only time will tell if ResMed can sustain its growth engine or if Philips Respironics’ return will be the catalyst for a new era of competition and innovation in the OSA space.
Reader Views
- QSQuinn S. · senior engineer
While ResMed's financials may look impressive, I'm concerned that investors are ignoring the elephant in the room: the impending entry of Philips Respironics into the US market. This could disrupt ResMed's dominance and erode its pricing power. What's also concerning is the lack of transparency around ResMed's product refresh cycle – when will we see new innovations to keep pace with competitors? The industry's focus on recurring revenue streams obscures the reality that devices become commoditized, leaving margins vulnerable to competition.
- AKAsha K. · self-taught dev
While ResMed's growth looks impressive, investors should be cautious about overemphasizing the importance of the AirSense platform. The article highlights its recurring revenue streams as a key strength, but what about the increasing trend towards cloud-connected devices? As more companies integrate remote monitoring and data analytics into their products, ResMed's business model may become less distinctive in a competitive market. Philips Respironics' return to the US could be a blessing in disguise, forcing ResMed to innovate and differentiate its offerings or risk being left behind.
- TSThe Stack Desk · editorial
While ResMed's financials may look stellar, don't be fooled by the rosy picture. The return of Philips Respironics looms large as a game-changer, threatening to disrupt ResMed's dominance in the US market. What's missing from this narrative is an examination of the long-term implications for patients. As manufacturers compete for market share, will quality and affordability suffer? Will patients be caught in the crossfire of industry tit-for-tat, forced to pay more for products that may not necessarily deliver better results? The article highlights the economic stakes but overlooks the human cost of this ongoing saga.